Tagged with RNA

USA The latest stories from healthcare and the life sciences in the US. The FDA names Stanford’s George Tidmarsh as the new head of CDER; AstraZeneca commits USD 50 billion to new US manufacturing and R&D projects; Moderna cancels its planned mRNA facility in Japan; Sarepta refuses to halt Elevidys shipments…

Switzerland What if the key to treating chronic and age-related diseases has been hidden in plain sight, within the 98 percent of the human genome once written off as “junk”? HAYA Therapeutics is betting on it. In this interview, CEO and Scientific Co-Founder Samir Ounzain reveals how his obsession with the…

Hong Kong Few biotech companies emerge with both scientific depth and a clear sense of direction. Innorna, founded by Dr Linxian Li after years spent refining RNA delivery systems in academic settings, is one of them. What began as a technical platform matured through a pandemic-era proof of concept and now moves…

Global The 2025 Davos World Economic Forum brought together business leaders from multiple industries to debate the challenges and issues facing the world today. The Pharma CEOs in attendance discussed critical topics such as the impact of climate change on health, AI-driven innovation, and the complexities of global trade tensions, all…

USA Naming a Chief Artificial Intelligence (AI) officer may not be an industry first, but Lilly’s recent creation of the role with the appointment of Thomas Fuchs confirms the solid commitment pharma has already made to introducing AI in processes that range from drug discovery to marketing.   AI Leaders Eli…

Global The 2024 Nobel Prize in Physiology or Medicine has been awarded to Victor Ambros and Gary Ruvkun, key figures in the development of microRNA; miniscule RNA molecules that enable cells to control which proteins they produce.   The Nobel Assembly of Sweden’s Karolinska Institute, which selects the prize’s winner said…

Japan A roundup of the most important stories coming out of Japan’s pharma industry, including the sharp increase in deaths linked to Kobayashi supplements; the partnership between Moderna and Mitsubishi Tanabe to jointly promote Moderna’s mRNA respiratory vaccine portfolio; the country’s move to to support domestic antibiotics production; Takeda’s licenscing agreement…

Global 35 years after the specific mechanisms and structure of the human immunodeficiency virus were first identified, the world is still waiting for a vaccine against HIV. Several late-stage candidates have failed in this time, leading to most of the major pharma companies exiting HIV vaccine research. Some new early-stage approaches…

Global IAS – the International AIDS Society – is a 13,000-plus member organisation that aims to unite the worlds of HIV science, policy, and activism, and organises the biennial International AIDS Conference among other activities. IAS Executive Director Birgit Poniatowski lays out what attendees at the upcoming conference in Munich this…

Saudi Arabia While international pharma has long been present in Saudi Arabia, the ambitious goals outlined in the country’s Vision 2030 economic transformation plan have encouraged companies to reinforce their commitment to the Kingdom. In recent PharmaBoardroom interviews, Saudi pharma country managers reveal their priorities and concerns.   Saudi Arabia holds immense…

Africa Medicines for Africa’s Lenias Hwenda reflects on Moderna’s recent decision not to go ahead with plans for a vaccine manufacturing facility in Kenya, and why local production remains crucial to building Africa’s healthcare autonomy.   In a turn of events that is both disappointing yet somehow not surprising, Moderna recently…

Global Having been quietly working away on its mRNA platform for years, Moderna stepped into the limelight during the COVID-19 pandemic and became a commercial-stage outfit almost overnight with its vaccine. After generating sales of USD 18.4 billion in 2022, demand for the company’s Spikevax shot, still its only commercialized product…